{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:43:35Z","timestamp":1784547815688,"version":"3.55.0"},"reference-count":244,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The incidence rate of breast cancer continues to grow worldwide and is increasingly occurring in younger women. Although treatments have improved, they present several distinct challenges, as life-threatening side effects, relapse, metastasis, and ultimately death in women and men of productive ages. The immunotherapeutic strategies are focused on the postoperative context, and the systemic intravenous therapies have shown benefits in some patient populations with overall survivor rates higher in hormone-dependent breast cancer, but still high relapse rates, especially in more aggressive cancers such as HER2+ and triple negative. To halt tumor progression, it is necessary to identify all players involved, but most importantly, acknowledge the interactions of tumor cells with their surroundings. The tumor microenvironment (TME) has emerged as a conceptual framework that underscores the collective influence of cellular, structural, and signaling elements coexisting around the tumor. These components do not merely act as passive bystanders; rather, they form a dynamic milieu that shapes tumor behavior, therapeutic responsiveness, and disease trajectory. This reinforces the notion that effective interventions must address not only malignant cells but also the broader contextual landscape in which they evolve. While intratumor refers to heterogeneity within a single tumor, the TME encompasses the surrounding non-cancerous cells, molecules, and vasculature that interact with the tumor, collectively forming a dynamic landscape that modulates therapeutic responses and disease trajectory. The neuro-immune-endocrine (NIE) network plays a complex role in breast cancer, with the nervous system influencing tumor growth, immune evasion, and metastasis through neurotransmitters and neuropeptides. The endocrine system influences the TME through hormones such as estrogens, even in non-estrogen-dependent tumors in breast cancer. At the same time, immune cells interact with both neural and endocrine components, responding through cytokine release and phenotype modulation, thereby mounting a permissive or cytotoxic response to combat tumors. Stress, which activates the sympathetic nervous system, can affect immune cells and hormone release, impacting treatment adherence and positive prognosis. Nowadays, local intratumoral delivery with diverse mechanisms of action has been shown to mitigate systemic toxic effects and ensure targeted delivery, and has progressed to clinical trials, demonstrating promising outcomes. These mechanisms include, but are not limited to, triggering immune responses using pathogens, enhancing immune responses with recombinant cytokines, inhibiting immune checkpoints with monoclonal antibodies, or combining two or more of these strategies. Despite the high mortality associated with breast cancer in aggressive subtypes and its characterization by well-defined primary lesions, the clinical application of non-systemic intratumoral chemotherapy remains limited. In this review, we summarize effective intratumoral immunotherapeutic approaches for inhibiting tumor growth and\/or metastasis in breast cancer. Specifically, we focus on the interactions within the NIE network that contribute to a sustained resolution of breast cancer. By elucidating these interactions, we aim to 1) predict treatment outcomes, 2) explain why some patients do not respond to innovative therapies, and 3) propose novel strategies for modifying the TME through targeted delivery of therapeutic agents with new materials. Furthermore, this approach paves the way for tumor-targeted modulation of other potential endocrine modulators, cytokine\/chemokine delivery, and neurotransmitter modulation within the TME, representing a novel frontier in cancer treatment.<\/jats:p>","DOI":"10.3389\/fonc.2026.1735300","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:23:16Z","timestamp":1771478596000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in intratumoral immunotherapy from a neuro-immune-endocrine perspective for breast cancer treatment"],"prefix":"10.3389","volume":"16","author":[{"given":"Claudia Ang\u00e9lica","family":"Garay-Canales","sequence":"first","affiliation":[{"name":"Neuroimmune Endocrine Interactions Laboratory, Instituto de Investigaciones Biom\u00e9dicas, Departamento de Inmunolog\u00eda, Universidad Nacional Aut\u00f3noma de M\u00e9xico","place":["Ciudad de M\u00e9xico, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Segovia-Mendoza","sequence":"additional","affiliation":[{"name":"Facultad de Medicina, Departamento de Farmacolog\u00eda, Universidad Nacional Aut\u00f3noma de M\u00e9xico","place":["Ciudad de M\u00e9xico, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Rodr\u00edguez-Santiago","sequence":"additional","affiliation":[{"name":"Neuroimmune Endocrine Interactions Laboratory, Instituto de Investigaciones Biom\u00e9dicas, Departamento de Inmunolog\u00eda, Universidad Nacional Aut\u00f3noma de M\u00e9xico","place":["Ciudad de M\u00e9xico, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Elizabeth","family":"Nava-Castro","sequence":"additional","affiliation":[{"name":"Laboratorio de Biolog\u00eda y Qu\u00edmica Atmosf\u00e9rica, Instituto de Ciencias de la Atm\u00f3sfera y Cambio Clim\u00e1tico, Departamento de Ciencias Ambientales, Universidad Nacional Aut\u00f3noma de M\u00e9xico","place":["Ciudad de M\u00e9xico, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda del Sol","family":"R\u00edos-Avila","sequence":"additional","affiliation":[{"name":"Laboratorio de Biolog\u00eda y Qu\u00edmica Atmosf\u00e9rica, Instituto de Ciencias de la Atm\u00f3sfera y Cambio Clim\u00e1tico, Departamento de Ciencias Ambientales, Universidad Nacional Aut\u00f3noma de M\u00e9xico","place":["Ciudad de M\u00e9xico, Mexico"]},{"name":"Posgrado en Ciencias Biol\u00f3gicas, Unidad de Posgrado, Universidad Nacional Aut\u00f3noma de M\u00e9xico","place":["Ciudad de M\u00e9xico, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe Esther \u00c1ngeles","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Facultad de Medicina, Departamento de Farmacolog\u00eda, Universidad Nacional Aut\u00f3noma de M\u00e9xico","place":["Ciudad de M\u00e9xico, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria Vargas Ponce","family":"de Le\u00f3n","sequence":"additional","affiliation":[{"name":"Facultad de Medicina, Departamento de Farmacolog\u00eda, Universidad Nacional Aut\u00f3noma de M\u00e9xico","place":["Ciudad de M\u00e9xico, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana L.","family":"Ruiz-Antonio","sequence":"additional","affiliation":[{"name":"Neuroimmune Endocrine Interactions Laboratory, Instituto de Investigaciones Biom\u00e9dicas, Departamento de Inmunolog\u00eda, Universidad Nacional Aut\u00f3noma de M\u00e9xico","place":["Ciudad de M\u00e9xico, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar Antonio","family":"Zavala-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Laboratorio de Biolog\u00eda y Qu\u00edmica Atmosf\u00e9rica, Instituto de Ciencias de la Atm\u00f3sfera y Cambio Clim\u00e1tico, Departamento de Ciencias Ambientales, Universidad Nacional Aut\u00f3noma de M\u00e9xico","place":["Ciudad de M\u00e9xico, Mexico"]},{"name":"Posgrado en Ciencias Biol\u00f3gicas, Unidad de Posgrado, Universidad Nacional Aut\u00f3noma de M\u00e9xico","place":["Ciudad de M\u00e9xico, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen T.","family":"G\u00f3mez de Le\u00f3n","sequence":"additional","affiliation":[{"name":"Neuroimmune Endocrine Interactions Laboratory, Instituto de Investigaciones Biom\u00e9dicas, Departamento de Inmunolog\u00eda, Universidad Nacional Aut\u00f3noma de M\u00e9xico","place":["Ciudad de M\u00e9xico, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Morales-Montor","sequence":"additional","affiliation":[{"name":"Neuroimmune Endocrine Interactions Laboratory, Instituto de Investigaciones Biom\u00e9dicas, Departamento de Inmunolog\u00eda, Universidad Nacional Aut\u00f3noma de M\u00e9xico","place":["Ciudad de M\u00e9xico, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/849720","article-title":"The Role of Chemokines in Breast Cancer Pathology and Its Possible Use as Therapeutic Targets","volume":"2014","author":"Palacios-Arreola","year":"2014","journal-title":"J Immunol Res"},{"key":"B2","unstructured":"Global Cancer Burden in 2022\n          \n          \n          Lyon, France\n          Global Cancer Today\n          \n          2022"},{"key":"B3","unstructured":"Washington D.C. USA\n          ENLACE data portal Pan American Health Organization\n          The burden of cancer in the Region of the Americas, 2000-2021\n          \n          2021"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/jir.2014.0026","article-title":"The role of cytokines in breast cancer development and progression","volume":"35","author":"Esquivel-Vel\u00e1zquez","year":"2015","journal-title":"J Interferon Cytokine Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/bcr1029","article-title":"The protective role of pregnancy in breast cancer","volume":"7","author":"Russo","year":"2005","journal-title":"Breast Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11912-023-01489-z","article-title":"Male Breast Cancer: a Review on Diagnosis, Treatment, and Survivorship","volume":"26","author":"Bhardwaj","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/15330338241261836","article-title":"Male Breast Cancer: Current Scenario and Future Perspectives","volume":"23","author":"Chidambaram","year":"2024","journal-title":"Technol Cancer Res Treat"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11080808","article-title":"Breast Cancer Treatments: Updates and New Challenges","volume":"11","author":"Burguin","year":"2021","journal-title":"J Pers Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0535","article-title":"Luminal A Breast Cancer and Molecular Assays: A Review","volume":"23","author":"Gao","year":"2018","journal-title":"Oncologist"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"B11","unstructured":"Maryland USA\n          SEER\n          Female Breast Cancer Subtypes - Cancer Stat Facts\n          \n          2025"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1054086","article-title":"Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer","volume":"12","author":"Huifang","year":"2022","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.610303","article-title":"The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy","volume":"11","author":"Salemme","year":"2021","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Sig Transd Targ Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15081","article-title":"Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer","volume":"8","author":"Chung","year":"2017","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00348","article-title":"Immune Tumor Microenvironment in Breast Cancer and the Participation of Estrogen and Its Receptors in Cancer Physiopathology","volume":"10","author":"Segovia-Mendoza","year":"2019","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.09.006","article-title":"Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells","volume":"26","author":"Ruffell","year":"2014","journal-title":"Cancer Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"12007","DOI":"10.1038\/s41598-022-16080-y","article-title":"GM-CSF derived from the inflammatory microenvironment potentially enhanced PD-L1 expression on tumor-associated macrophages in human breast cancer","volume":"12","author":"Yonemitsu","year":"2022","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32030143","article-title":"Breast Cancer and Tumor Microenvironment: The Crucial Role of Immune Cells","volume":"32","author":"Moura","year":"2025","journal-title":"Curr Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.772615","article-title":"Tumor-Associated Macrophages: Key Players in Triple-Negative Breast Cancer","volume":"12","author":"Qiu","year":"2022","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101134","article-title":"The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis","volume":"41","author":"Li","year":"2021","journal-title":"eClinicalMedicine"},{"key":"B24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3892\/ol.2022.13625","article-title":"Prognostic value of CD8+ tumor\u2212infiltrating T cells in patients with breast cancer: A systematic review and meta\u2212analysis","volume":"25","author":"Sun","year":"2022","journal-title":"Oncol Lett"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a030338","article-title":"T Helper Cell Differentiation, Heterogeneity, and Plasticity","volume":"10","author":"Zhu","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00600.x","article-title":"Polarized immune responses differentially regulate cancer development","volume":"222","author":"Johansson","year":"2008","journal-title":"Immunol Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0226950","DOI":"10.1371\/journal.pone.0226950","article-title":"Can atopy have a protective effect against cancer","volume":"15","author":"Bo\u017cek","year":"2020","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e20201963","DOI":"10.1084\/jem.20201963","article-title":"CD4+ T helper 2 cells suppress breast cancer by inducing terminal differentiation","volume":"219","author":"Boieri","year":"2022","journal-title":"J Exp Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12967-015-0535-8","article-title":"Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery","volume":"13","author":"Verma","year":"2015","journal-title":"J Transl Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1200282","article-title":"Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0691","article-title":"Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function","volume":"24","author":"Stiff","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.1.240","article-title":"Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-\u03b21","volume":"182","author":"Li","year":"2009","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.108803","article-title":"Unraveling the breast cancer tumor microenvironment: crucial factors influencing natural killer cell function and therapeutic strategies","volume":"21","author":"Li","year":"2025","journal-title":"Int J Biol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/676198","article-title":"Natural Killer Cells in Human Cancer: From Biological Functions to Clinical Applications","volume":"2011","author":"Levy","year":"2011","journal-title":"BioMed Res Int"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0684","article-title":"Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer","volume":"10","author":"Treilleux","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"101913","DOI":"10.1016\/j.gendis.2025.101913","article-title":"Dendritic cell vaccines: Current research progress, challenges, and opportunities","author":"Zhang","year":"2025","journal-title":"Genes Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01680","article-title":"The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion","volume":"11","author":"De Cicco","year":"2020","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2015.02.024","article-title":"Activation of neuroimmune pathways increases therapeutic effects of radiotherapy on poorly differentiated breast carcinoma","volume":"48","author":"Erin","year":"2015","journal-title":"Brain Behav Immun"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1038\/s41467-018-05220-6","article-title":"Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer","volume":"9","author":"Cazet","year":"2018","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-02973-x","article-title":"Cancer-associated fibroblasts rewire the estrogen receptor response in luminal breast cancer, enabling estrogen independence","volume":"43","author":"Reid","year":"2024","journal-title":"Oncogene"},{"key":"B41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13058-019-1131-2","article-title":"The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells","volume":"21","author":"Ryan","year":"2019","journal-title":"Breast Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00532","article-title":"An Attempt to Polarize Human Neutrophils Toward N1 and N2 Phenotypes","volume":"11","author":"Ohms","year":"2020","journal-title":"Vitro Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24044002","article-title":"Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment","volume":"24","author":"Habanjar","year":"2023","journal-title":"IJMS"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02584-4","article-title":"Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions","volume":"42","author":"Jayachandran","year":"2023","journal-title":"Oncogene"},{"key":"B45","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/BD-2007-26107","article-title":"Chemokine Networks and Breast Cancer Metastasis","volume":"26","author":"Karnoub","year":"2007","journal-title":"BD"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.7150\/thno.81403","article-title":"Exploring neurotransmitters and their receptors for breast cancer prevention and treatment","volume":"13","author":"Li","year":"2023","journal-title":"Theranostics"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.155909","article-title":"Role of chemokines in breast cancer","volume":"155","author":"Masih","year":"2022","journal-title":"Cytokine"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13402-019-00489-1","article-title":"The dual role of tumor necrosis factor-alpha (TNF-\u03b1) in breast cancer: molecular insights and therapeutic approaches","volume":"43","author":"Cruceriu","year":"2020","journal-title":"Cell Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2007.10.005","article-title":"TNF\u03b1 acting on TNFR1 promotes breast cancer growth via p42\/P44 MAPK, JNK, Akt and NF-\u03baB-dependent pathways","volume":"314","author":"Rivas","year":"2008","journal-title":"Exp Cell Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22264","article-title":"TNFalpha up-regulates SLUG via the NF-kappaB\/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype","volume":"225","author":"Storci","year":"2010","journal-title":"J Cell Physiol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-016-0280-x","article-title":"TNF-\u03b1 promotes breast cancer cell migration and enhances the concentration of membrane-associated proteases in lipid rafts","volume":"39","author":"Wolczyk","year":"2016","journal-title":"Cell Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2174\/156800908783769346","article-title":"Tumor necrosis factor: renaissance as a cancer therapeutic","volume":"8","author":"Daniel","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"key":"B53","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1186\/s12885-016-2746-7","article-title":"IL-1\u03b2 induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells","volume":"16","author":"Oh","year":"2016","journal-title":"BMC Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.866014","article-title":"IL-6\/JAK\/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment","volume":"12","author":"Manore","year":"2022","journal-title":"Front Oncol"},{"key":"B55","first-page":"38","article-title":"Assessing the Role of the Interleukin-12\/STAT4 Axis in Breast Cancer by a Bioinformatics Approach","volume":"48","author":"N\u00fa\u00f1ez-Marrero","year":"2019","journal-title":"Int J Sci Basic Appl Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.283","article-title":"Combined Tbet and IL12 Gene Therapy Elicits and Recruits Superior Antitumor Immunity In Vivo","volume":"20","author":"Qu","year":"2012","journal-title":"Mol Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1032","article-title":"Restoration of Natural Killer Cell Antimetastatic Activity by IL12 and Checkpoint Blockade","volume":"77","author":"Ohs","year":"2017","journal-title":"Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.7114","article-title":"IL-12 induces autophagy in human breast cancer cells through AMPK and the PI3K\/Akt pathway","volume":"16","author":"Lin","year":"2017","journal-title":"Mol Med Rep"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/925135","article-title":"CD4+ T Cells: Differentiation and Functions","volume":"2012","author":"Luckheeram","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.08.004","article-title":"Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity","volume":"33","author":"Malek","year":"2010","journal-title":"Immunity"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.02.021","article-title":"Th17 and Regulatory T Cells in Mediating and Restraining Inflammation","volume":"140","author":"Littman","year":"2010","journal-title":"Cell"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.67","article-title":"Interferon-\u03b3 derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity","volume":"8","author":"Bhat","year":"2017","journal-title":"Cell Death Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2011.91","article-title":"Induction of metastatic cancer stem cells from the NK\/LAK-resistant floating, but not adherent, subset of the UP-LN1 carcinoma cell line by IFN-\u03b3","volume":"91","author":"Chen","year":"2011","journal-title":"Lab Invest"},{"key":"B64","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","article-title":"Conserved Interferon-\u03b3 Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma","volume":"38","author":"Grasso","year":"2020","journal-title":"Cancer Cell"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2015.23","article-title":"Chemokines, their receptors and human disease: the good, the bad and the itchy","volume":"93","author":"Bryant","year":"2015","journal-title":"Immunol Cell Biol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.03.008","article-title":"Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications","volume":"86","author":"Mehraj","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"R23","DOI":"10.1186\/bcr3108","article-title":"Contribution of CXCL12 secretion to invasion of breast cancer cells","volume":"14","author":"Boimel","year":"2012","journal-title":"Breast Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0014","article-title":"CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer","volume":"11","author":"Cabioglu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.02.034","article-title":"Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1\/CXCL12 Secretion","volume":"121","author":"Orimo","year":"2005","journal-title":"Cell"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2016.148","article-title":"NF-\u03baB signaling regulates cell-autonomous regulation of CXCL10 in breast cancer 4T1 cells","volume":"49","author":"Jin","year":"2017","journal-title":"Exp Mol Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2011.953","article-title":"CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion","volume":"38","author":"Johnson-Holiday","year":"2011","journal-title":"Int J Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20141836","article-title":"CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages","volume":"212","author":"Kitamura","year":"2015","journal-title":"J Exp Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2016_017","article-title":"Altered levels of plasma chemokines in breast cancer and their association with clinical and pathological characteristics","volume":"63","author":"Narita","year":"2016","journal-title":"NEO"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e20898","DOI":"10.1371\/journal.pone.0020898","article-title":"Differential Estrogen-Regulation of CXCL12 Chemokine Receptors, CXCR4 and CXCR7, Contributes to the Growth Effect of Estrogens in Breast Cancer Cells","volume":"6","author":"Boudot","year":"2011","journal-title":"PloS One"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0204","article-title":"CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer","volume":"21","author":"Svensson","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1006\/cimm.1994.1262","article-title":"Estrogen Induces Suppression of Natural Killer Cell Cytotoxicity and Augmentation of Polyclonal B Cell Activation","volume":"158","author":"Nilsson","year":"1994","journal-title":"Cell Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0008-8749(87)90163-8","article-title":"Estrogen and antiestrogen modulation of the levels of mouse natural killer activity and large granular lymphocytes","volume":"106","author":"Screpanti","year":"1987","journal-title":"Cell Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.5114\/pjr\/189566","article-title":"Physiological changes in the mammary glands during a female\u2019s life","volume":"89","author":"Katulski","year":"2024","journal-title":"Pol J Radiol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/febs.17270","article-title":"Estrogen receptors and extracellular matrix: the critical interplay in cancer development and progression","volume":"292","author":"Mangani","year":"2025","journal-title":"FEBS J"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-4_Part_1-199902160-00004","article-title":"for the Study of Osteoporotic Fractures Research Group. Elevated Serum Estradiol and Testosterone Concentrations Are Associated with a High Risk for Breast Cancer","volume":"130","author":"Cauley","year":"1999","journal-title":"Ann Intern Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"293","DOI":"10.4103\/bbrj.bbrj_59_20","article-title":"The Role of Estrogen in Breast Cancer","volume":"4","author":"Khadem","year":"2020","journal-title":"Biomed Biotechnol Res J (BBRJ)"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(97)80022-2","article-title":"Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible","volume":"61","author":"Santen","year":"1997","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B83","volume-title":"RISING STARS: Hormonal regulation of the breast cancer microenvironment","author":"Boyle","year":"2023"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050776","article-title":"Estrogen Carcinogenesis in Breast Cancer","volume":"354","author":"Yager","year":"2006","journal-title":"New Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(03)00377-7","article-title":"Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis","volume":"86","author":"Yue","year":"2003","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0941-0","article-title":"Dynamic interactions between the extracellular matrix and estrogen activity in progression of ER+ breast cancer","volume":"38","author":"Jallow","year":"2019","journal-title":"Oncogene"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1210\/endo.142.7.8273","article-title":"Fibronectin and the \u03b15\u03b21 Integrin Are Under Developmental and Ovarian Steroid Regulation in the Normal Mouse Mammary Gland","volume":"142","author":"Woodward","year":"2001","journal-title":"Endocrinology"},{"key":"B88","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/01.ATV.21.1.6","article-title":"Estrogen and Angiogenesis: A Review","volume":"21","author":"Losordo","year":"2001","journal-title":"ATVB"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01657","article-title":"Involvement of the Estrogen and Progesterone Axis in Cancer Stemness: Elucidating Molecular Mechanisms and Clinical Significance","volume":"10","author":"Chen","year":"2020","journal-title":"Front Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.298","article-title":"Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a","volume":"34","author":"Finlay-Schultz","year":"2015","journal-title":"Oncogene"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.404871","article-title":"Estrogen Receptor \u03b1 Signaling Regulates Breast Tumor-initiating Cells by Down-regulating miR-140 Which Targets the Transcription Factor SOX2 *","volume":"287","author":"Zhang","year":"2012","journal-title":"J Biol Chem"},{"key":"B92","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1097\/MD.0000000000004765","article-title":"Cancer stem cell signaling pathways","volume":"95","author":"Matsui","year":"2016","journal-title":"Medicine"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065867","article-title":"Estrogen Receptor \u03b24 Regulates Chemotherapy Resistance and Induces Cancer Stem Cells in Triple Negative Breast Cancer","volume":"24","author":"Bano","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.5","article-title":"TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells","volume":"34","author":"Bartucci","year":"2015","journal-title":"Oncogene"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.09.048","article-title":"The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells","volume":"147","author":"Cordenonsi","year":"2011","journal-title":"Cell"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00379","article-title":"Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy","volume":"10","author":"Mollica Poeta","year":"2019","journal-title":"Front Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1118637","article-title":"Neurotransmitters: promising immune modulators in the tumor microenvironment","volume":"14","author":"Xiao","year":"2023","journal-title":"Front Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1778","article-title":"Dopamine Increases the Efficacy of Anticancer Drugs in Breast and Colon Cancer Preclinical Models","volume":"14","author":"Sarkar","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2022.2047173","article-title":"Impact of the prolactin levels in breast cancer: a systematic review and meta-analysis","volume":"38","author":"Aranha","year":"2022","journal-title":"Gynecol Endocrinol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/srep45686","article-title":"Inhibitory Effects of Dopamine Receptor D1 Agonist on Mammary Tumor and Bone Metastasis","volume":"7","author":"Minami","year":"2017","journal-title":"Sci Rep"},{"key":"B101","doi-asserted-by":"publisher","first-page":"R81","DOI":"10.1186\/bcr2448","article-title":"Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival","volume":"11","author":"Pai","year":"2009","journal-title":"Breast Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06402-5","article-title":"Expression of neurotensin receptor-1 (NTS1) in primary breast tumors, cellular distribution, and association with clinical and biological factors","volume":"190","author":"Morgat","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0450","article-title":"Expression of Neurotensin and NT1 Receptor in Human Breast Cancer: A Potential Role in Tumor Progression","volume":"66","author":"Souaz\u00e9","year":"2006","journal-title":"Cancer Res"},{"key":"B104","article-title":"Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets","volume":"61","author":"Reubi","year":"2001","journal-title":"Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/00000658-189407000-00075","article-title":"The results of operations for the cure of cancer of the breast performed at the johns hopkins hospital from June, 1889, to January","volume":"20","author":"Halsted","year":"1894","journal-title":"Ann Surg"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020128","article-title":"Twenty-Five-Year Follow-up of a Randomized Trial Comparing Radical Mastectomy, Total Mastectomy, and Total Mastectomy Followed by Irradiation","volume":"347","author":"Fisher","year":"2002","journal-title":"N Engl J Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27408","article-title":"Oncoplastic surgery for breast cancer: Global perspectives and trends","volume":"128","author":"Armstrong","year":"2023","journal-title":"J Surg Oncol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jamasurg.2013.3049","article-title":"Effect of Breast Conservation Therapy vs Mastectomy on Disease-Specific Survival for Early-Stage Breast Cancer","volume":"149","author":"Agarwal","year":"2014","journal-title":"JAMA Surg"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27795","article-title":"Survival after lumpectomy and mastectomy for early stage invasive breast cancer: The effect of age and hormone receptor status","volume":"119","author":"Hwang","year":"2013","journal-title":"Cancer"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv107","article-title":"Survival in stage I\u2013III breast cancer patients by surgical treatment in a publicly funded health care system","volume":"26","author":"Fisher","year":"2015","journal-title":"Ann Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2017.01.012","article-title":"What influences healthcare professionals\u2019 treatment preferences for older women with operable breast cancer? An application of the discrete choice experiment","volume":"43","author":"Morgan","year":"2017","journal-title":"Eur J Surg Oncol (EJSO)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2015.0577","article-title":"The Treatment of Primary Breast Cancer in Older Women With Adjuvant Therapy","volume":"112","author":"Peters","year":"2015","journal-title":"Deutsh \u00c4rztebl Int"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.9733","article-title":"Oncoplastic and reconstructive breast surgery in the elderly","volume":"102","author":"James","year":"2015","journal-title":"Br J Surg"},{"key":"B114","unstructured":"National Cancer Institute\n          \n          2023"},{"key":"B115","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70246-1","article-title":"New insights on cell death from radiation exposure","volume":"6","author":"Prise","year":"2005","journal-title":"Lancet Oncol"},{"key":"B117","article-title":"Radiotherapy","volume-title":"Handbook of Clinical Neurology","author":"Minniti","year":"2012"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000515)88:10<2260::AID-CNCR9>3.0.CO;2-M","article-title":"The effects of radiation therapy on quality of life of women with breast carcinoma: results of a randomized trial","volume":"88","author":"Whelan","year":"2000","journal-title":"Ont Clin Oncol Group Cancer"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/pon.1734","article-title":"A qualitative analysis of acute skin toxicity among breast cancer radiotherapy patients","volume":"20","author":"Schnur","year":"2011","journal-title":"Psycho-Oncology"},{"key":"B120","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13014-025-02663-2","article-title":"Risk factors for severity of breast cancer-related lymphedema","volume":"20","author":"Bahanesteh","year":"2025","journal-title":"Radiat Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32514-0","article-title":"Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial","volume":"394","author":"Vicini","year":"2019","journal-title":"Lancet"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.09.001","article-title":"Second Solid Cancers After Radiation Therapy: A Systematic Review of the Epidemiologic Studies of the Radiation Dose-Response Relationship","volume":"86","author":"Berrington De Gonzalez","year":"2013","journal-title":"Int J Radiat OncolBiolPhys"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2020.05.003","article-title":"Novel radiation therapy approaches for breast cancer treatment","volume":"47","author":"Shah","year":"2020","journal-title":"Semin Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.canrad.2021.11.013","article-title":"Radiotherapy of breast cancer","volume":"26","author":"Hennequin","year":"2022","journal-title":"Cancer\/Radioth\u00e9rapie"},{"key":"B126","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s00066-022-01979-2","article-title":"Three-dimensional conformal radiotherapy (3D-CRT) vs. volumetric modulated arc therapy (VMAT) in deep inspiration breath-hold (DIBH) technique in left-sided breast cancer patients\u2014comparative analysis of dose distribution and estimation of projected secondary cancer risk","volume":"199","author":"Racka","year":"2023","journal-title":"Strahlenther Onkol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1002\/jmrs.530","article-title":"New fractionations in breast cancer: a dosimetric study of 3D-CRT versus VMAT","volume":"69","author":"Piras","year":"2022","journal-title":"J Med Radiat Sci"},{"key":"B128","unstructured":"Cancer Chemotherapy\n          \n          \n            \n              Amjad\n              MT\n            \n            \n              Chidharla\n              A\n            \n            \n              Kasi\n              A\n            \n          \n          Treasure Island (FL\n          StatPearls Publishing\n          StatPearls\n          \n          2025"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A History of Cancer Chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.960317","article-title":"Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action","volume":"12","author":"Tilsed","year":"2022","journal-title":"Front Oncol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101056","article-title":"Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells","volume":"14","author":"Mollaei","year":"2021","journal-title":"Trans Oncol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.4137\/BCBCR.S9454","article-title":"Update on adjuvant chemotherapy for early breast cancer","volume":"8","author":"Rampurwala","year":"2014","journal-title":"Breast Cancer (Auckl)"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.3062","article-title":"Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis","volume":"1","author":"Fujii","year":"2015","journal-title":"JAMA Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100\u2013000 women in 123 randomised trials","volume":"379","year":"2012","journal-title":"Lancet"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100\u2013000 women from 86 randomised trials","volume":"401","author":"Braybrooke","year":"2023","journal-title":"Lancet"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.hsr.2023.100119","article-title":"An update on breast cancer chemotherapy-associated toxicity and their management approaches","volume":"9","author":"Langeh","year":"2023","journal-title":"Health Sci Rev"},{"key":"B137","doi-asserted-by":"publisher","first-page":"FSO617","DOI":"10.2144\/fsoa-2020-0076","article-title":"Side Effects of Adjuvant Chemotherapy and their Impact on Outcome in Elderly Breast Cancer Patients: A Cohort Study","volume":"6","author":"Zanuso","year":"2020","journal-title":"Future Sci OA"},{"key":"B138","doi-asserted-by":"publisher","first-page":"863","DOI":"10.18553\/jmcp.2015.21.10.863","article-title":"Clinical Impact of Chemotherapy-Related Adverse Events in Patients with Metastatic Breast Cancer in an Integrated Health Care System","volume":"21","author":"Rashid","year":"2015","journal-title":"JMCP"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2023.1537","article-title":"Evaluation of side effects and compliance to chemotherapy in breast cancer patients at a Nigerian tertiary hospital","volume":"17","author":"Folorunso","year":"2023","journal-title":"ECANCER"},{"key":"B140","doi-asserted-by":"publisher","first-page":"e38301","DOI":"10.7759\/cureus.38301","article-title":"The Incidence and Severity of Patient-Reported Side Effects of Chemotherapy in Routine Clinical Care: A Prospective Observational Study","volume":"15","author":"Katta","year":"2023","journal-title":"Cureus"},{"key":"B141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-812373-7.00001-2","article-title":"Pathways Linked to Cancer Chemoresistance and Their Targeting by Nutraceuticals","volume-title":"Role of Nutraceuticals in Chemoresistance to Cancer","author":"Bharti","year":"2018"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00758-0","article-title":"Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials","volume":"23","author":"Bradley","year":"2022","journal-title":"Lancet Oncol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1586\/era.11.96","article-title":"Current role and safety profile of aromatase inhibitors in early breast cancer","volume":"11","author":"Tomao","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"B144","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1570163812666150602144310","article-title":"Targeted Cancer Therapy: The Next Generation of Cancer Treatment","volume":"12","author":"Baudino","year":"2015","journal-title":"CDDT"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106","article-title":"Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2\/neu Oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"B146","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","article-title":"The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Koboldt","year":"2012","journal-title":"Nature"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1749-6632.1995.tb12113.x","article-title":"The Role of Estrogen in Mammary Carcinogenesisa","volume":"768","author":"Fishman","year":"1995","journal-title":"Ann New York Acad Sci"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.05.023","article-title":"Estrogen signaling: An emanating therapeutic target for breast cancer treatment","volume":"177","author":"Saha","year":"2019","journal-title":"Eur J Med Chem"},{"key":"B150","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/tpj.2014.34","article-title":"Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer","volume":"15","author":"Saladores","year":"2015","journal-title":"Pharmacogenomics J"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00288-6","article-title":"Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13\u2013864 women in seven randomised trials","volume":"22","author":"Bradley","year":"2021","journal-title":"Lancet Oncol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00551-3","article-title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Chan","year":"2016","journal-title":"Lancet Oncol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2020.12241","article-title":"Efficacy of lapatinib combined with capecitabine in patients with HER2\u2212positive metastatic breast cancer in a real\u2212world study","volume":"20","author":"Gui","year":"2020","journal-title":"Oncol Lett"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With \u2265 2 HER2-Directed Regimens: Phase III NALA Trial","volume":"38","author":"Saura","year":"2020","journal-title":"JCO"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.2174\/0115680096266181231207110048","article-title":"Efficacy and Safety of Phosphatidylinositol 3-kinase Inhibitors forPatients with Breast Cancer: A Systematic Review and Meta-analysis ofRandomized Controlled Trials","volume":"24","author":"Wang","year":"2024","journal-title":"CCDT"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.956464","article-title":"CDK4\/6 inhibitors versus PI3K\/AKT\/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials","volume":"12","author":"Xu","year":"2022","journal-title":"Front Oncol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1438288","article-title":"Adjuvant and neoadjuvant therapy with or without CDK4\/6 inhibitors in HR+\/HER2- early breast cancer: a systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Pharmacol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e13069","article-title":"Efficacy of everolimus-containing chemotherapy in HER2 negative metastatic breast cancer patients with PI3K\/AKT\/mTOR mutations: A retrospective study","volume":"39","author":"Wang","year":"2021","journal-title":"JCO"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14486","article-title":"The Future of ER+\/HER2\u2013 Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors","volume":"40","author":"Stravodimou","year":"2020","journal-title":"Anticancer Res"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"B161","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/jamaoncol.2023.5424","article-title":"Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial","volume":"10","author":"Lehmann","year":"2024","journal-title":"JAMA Oncol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12935-023-02941-7","article-title":"Comparative efficacy and safety of PD-1\/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials","volume":"23","author":"Elmakaty","year":"2023","journal-title":"Cancer Cell Int"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab Deruxtecan in Advanced or Metastatic HR+\/HER2\u2013 and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study","volume":"42","author":"Bardia","year":"2024","journal-title":"JCO"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16213622","article-title":"Sacituzumab Govitecan in Triple Negative Breast Cancer: A Systematic Review of Clinical Trials","volume":"16","author":"P\u00e9rez-Bermejo","year":"2024","journal-title":"Cancers"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0310","article-title":"Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG\/BIG5\u201313\/TESARO PR-30\u201350\u201310-C BRAVO Study","volume":"27","author":"Turner","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v8.i2.120","article-title":"Targeted therapies in breast cancer: New challenges to fight against resistance","volume":"8","author":"Masoud","year":"2017","journal-title":"WJCO"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1479483","article-title":"Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer","volume":"15","author":"Skalickova","year":"2025","journal-title":"Front Immunol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2022.2069097","article-title":"What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy","volume":"22","author":"Bilusic","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyz213","article-title":"Adjuvant and neoadjuvant therapy for breast cancer","volume":"50","author":"Shien","year":"2020","journal-title":"Japan J Clin Oncol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102375","article-title":"Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality","volume":"105","author":"Kerr","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B174","unstructured":"Cancer treatment side effects\n          \n          2025"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1385484","article-title":"Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies","volume":"15","author":"Mantooth","year":"2024","journal-title":"Front Immunol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041132","article-title":"Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes","volume":"15","author":"Chang","year":"2023","journal-title":"Pharmaceutics"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29551","article-title":"In situ antitumor vaccination: Targeting the tumor microenvironment","volume":"235","author":"Li","year":"2020","journal-title":"J Cell Physiol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114505","article-title":"Image-guided intratumoral immunotherapy: Developing a clinically practical technology","volume":"189","author":"Som","year":"2022","journal-title":"Adv Drug Del Rev"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtadv.2024.100539","article-title":"Advancing cancer immunotherapy through emerging intratumoral delivery and biomedical imaging technologies","volume":"24","author":"Choi","year":"2024","journal-title":"Mater Today Adv"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S467835","article-title":"Development of Intratumoral Drug Delivery Based Strategies for Antitumor Therapy","volume":"18","author":"Jiang","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.04.012","article-title":"Stimuli-responsive hydrogels for intratumoral drug delivery","volume":"26","author":"Marques","year":"2021","journal-title":"Drug Discov Today"},{"key":"B182","doi-asserted-by":"publisher","first-page":"e968001","DOI":"10.4161\/21624011.2014.968001","article-title":"Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis","volume":"3","author":"Vo","year":"2014","journal-title":"OncoImmunology"},{"key":"B183","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.ccell.2021.08.005","article-title":"Activating a collaborative innate-adaptive immune response to control metastasis","volume":"39","author":"Sun","year":"2021","journal-title":"Cancer Cell"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S201421","article-title":"A temperature-sensitive phase-change hydrogel of tamoxifen achieves the long-acting antitumor activation on breast cancer cells","volume":"12","author":"Meng","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.3109\/1061186X.2010.499461","article-title":"Injectable delivery system of 2-methoxyestradiol for breast cancer therapy using biodegradable thermosensitive poly(organophosphazene) hydrogel","volume":"19","author":"Cho","year":"2011","journal-title":"J Drug Targeting"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113761","article-title":"An injectable hydrogel enhances intratumoral retention and antitumor efficacy of cytokine immunotherapy in murine triple negative breast tumor models","volume":"383","author":"Mantooth","year":"2025","journal-title":"J Controlled Rel"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202401376","article-title":"Targeted Delivery of Circular Single-Stranded DNA Encoding IL-12 for the Treatment of Triple-Negative Breast Cancer","volume":"13","author":"Zhang","year":"2024","journal-title":"Adv Healthc Mater"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2015.42","article-title":"Modulating mammary tumor growth, metastasis and immunosuppression by siRNA-induced MIF reduction in tumor microenvironment","volume":"22","author":"Zhang","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"B189","doi-asserted-by":"publisher","first-page":"eaax4690","DOI":"10.1126\/sciadv.aax4690","article-title":"Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9+ T cells","volume":"6","author":"Chen","year":"2020","journal-title":"Sci Adv"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2004.03.022","article-title":"Intratumoral IL-12 and TNF-\u03b1\u2013Loaded Microspheres Lead To Regression of Breast Cancer and Systemic Antitumor Immunity","volume":"11","author":"Sabel","year":"2004","journal-title":"Ann Surg Oncol"},{"key":"B191","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ebiom.2018.09.050","article-title":"In situ administration of cytokine combinations induces tumor regression in mice","volume":"37","author":"Zhang","year":"2018","journal-title":"EBioMedicine"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.cis.2024.103124","article-title":"Effect of biophysical properties of tumor extracellular matrix on intratumoral fate of nanoparticles: Implications on the design of nanomedicine","volume":"326","author":"Tian","year":"2024","journal-title":"Adv Colloid Interface Sci"},{"key":"B193","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jconrel.2022.06.050","article-title":"Recent advances in nanoparticle-based photothermal therapy for breast cancer","volume":"349","author":"Alamdari","year":"2022","journal-title":"J Controlled Rel"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124687","article-title":"Breaking barriers in cancer management: The promising role of microsphere conjugates in cancer diagnosis and therapy","volume":"665","author":"Gupta","year":"2024","journal-title":"Int J Pharmaceutics"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.104402","article-title":"Cancer theranostics employing microneedles: Experimental and patented strategies","volume":"83","author":"Alshammari","year":"2023","journal-title":"J Drug Del Sci Technol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202312088","article-title":"Microneedle-Mediated Delivery of Immunomodulators Restores Immune Privilege in Hair Follicles and Reverses Immune-Mediated Alopecia","volume":"36","author":"Younis","year":"2024","journal-title":"Adv Mater"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1456658","article-title":"Intratumoral injection and retention hold promise to improve cytokine therapies for cancer","volume":"14","author":"Sauer","year":"2024","journal-title":"Front Oncol"},{"key":"B198","doi-asserted-by":"publisher","first-page":"84","DOI":"10.36401\/JIPO-22-8","article-title":"The Contemporary Landscape and Future Directions of Intratumoral Immunotherapy","volume":"6","author":"Brito-Orama","year":"2023","journal-title":"J Immunother Precis Oncol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126806","article-title":"Breast Cancer Metastasis: Mechanisms and Therapeutic Implications","volume":"23","author":"Park","year":"2022","journal-title":"IJMS"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1007\/s12195-021-00679-8","article-title":"Immune System Effects on Breast Cancer","volume":"14","author":"Amens","year":"2021","journal-title":"Cel Mol Bioeng"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1627","article-title":"Intratumoral Cytokines and Tumor Cell Biology Determine Spontaneous Breast Cancer\u2013Specific Immune Responses and Their Correlation to Prognosis","volume":"69","author":"Domschke","year":"2009","journal-title":"Cancer Res"},{"key":"B202","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/imr.13234","article-title":"Spatiotemporally programming cytokine immunotherapies through protein engineering","volume":"320","author":"Santollani","year":"2023","journal-title":"Immunol Rev"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00746-x","article-title":"Strategies to therapeutically modulate cytokine action","volume":"22","author":"Leonard","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B204","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1089\/jir.2018.0024","article-title":"Breast Cancer Metastasis: Are Cytokines Important Players During Its Development and Progression","volume":"39","author":"M\u00e9ndez-Garc\u00eda","year":"2019","journal-title":"J Interferon Cytokine Res"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2488-z","article-title":"The role of intratumoral and systemic IL-6 in breast cancer","volume":"138","author":"Dethlefsen","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.969.3.8","article-title":"Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody","volume":"3","author":"Rakhmilevich","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.682708","article-title":"Interleukin 10 (IL-10)-mediated Immunosuppression","volume":"290","author":"Mittal","year":"2015","journal-title":"J Biol Chem"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.8b00967","article-title":"Local Blockade of Interleukin 10 and C-X-C Motif Chemokine Ligand 12 with Nano-Delivery Promotes Antitumor Response in Murine Cancers","volume":"12","author":"Shen","year":"2018","journal-title":"ACS Nano"},{"key":"B209","article-title":"Overcoming the limitations of cytokines to improve cancer therapy","volume-title":"International Review of Cell and Molecular Biology","author":"Di Trani","year":"2022"},{"key":"B210","doi-asserted-by":"publisher","first-page":"e1011740","DOI":"10.1371\/journal.pcbi.1011740","article-title":"Mathematical modeling of intratumoral immunotherapy yields strategies to improve the treatment outcomes","volume":"19","author":"Harkos","year":"2023","journal-title":"PloS Comput Biol"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2013.837886","article-title":"Targeting CCL5 in inflammation","volume":"17","author":"Marques","year":"2013","journal-title":"Expert Opin Ther Targets"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.82317","article-title":"CXCL12-CXCR4\/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications","volume":"19","author":"Yang","year":"2023","journal-title":"Int J Biol Sci"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1016\/j.humgen.2024.201272","article-title":"Unravelling the CXCL12\/CXCR4 Axis in breast cancer: Insights into metastasis, microenvironment interactions, and therapeutic opportunities","volume":"40","author":"Garg","year":"2024","journal-title":"Hum Gene"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7376","article-title":"Targeting the CCL2-CCR2 signaling axis in cancer metastasis","volume":"7","author":"Lim","year":"2016","journal-title":"Oncotarget"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-02174-w","article-title":"Subsets of cancer cells expressing CX3CR1 are endowed with metastasis-initiating properties and resistance to chemotherapy","volume":"41","author":"DiNatale","year":"2022","journal-title":"Oncogene"},{"key":"B216","doi-asserted-by":"publisher","first-page":"R128","DOI":"10.1186\/bcr3074","article-title":"Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis","volume":"13","author":"Hernandez","year":"2011","journal-title":"Breast Cancer Res"},{"key":"B217","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s42003-020-01441-y","article-title":"Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy","volume":"3","author":"Tu","year":"2020","journal-title":"Commun Biol"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-9-46","article-title":"CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion","volume":"9","author":"Johnson-Holiday","year":"2011","journal-title":"World J Surg Onc"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.04.042","article-title":"A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis","volume":"150","author":"Acharyya","year":"2012","journal-title":"Cell"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3917","article-title":"CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells","volume":"72","author":"Velasco-Vel\u00e1zquez","year":"2012","journal-title":"Cancer Res"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39397","article-title":"CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts","volume":"120","author":"Ginestier","year":"2010","journal-title":"J Clin Invest"},{"key":"B222","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0014-5793(03)00824-X","article-title":"T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer","volume":"550","author":"Tamamura","year":"2003","journal-title":"FEBS Lett"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.1651","article-title":"CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2\/neu DNA vaccination model","volume":"14","author":"Nguyen-Hoai","year":"2012","journal-title":"J Gene Med"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1220580110","article-title":"Targeting CXCL12\/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases","volume":"110","author":"Gil","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B225","volume-title":"The Innate Immune System in Health and Disease: From the Lab Bench Work to Its Clinical Implications","author":"Morales-Montor","year":"2022"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.70120","article-title":"CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application","volume":"18","author":"Yang","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115899","article-title":"CAR-NK Cells in the Treatment of Solid Tumors","volume":"22","author":"Wrona","year":"2021","journal-title":"IJMS"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13040429","article-title":"Intratumoral Immunotherapy in Breast Cancer","volume":"13","author":"Baumrucker","year":"2025","journal-title":"Vaccines"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(99)00048-5","article-title":"Intratumoral levels of estrogens in breast cancer","volume":"69","author":"Blankenstein","year":"1999","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(03)00368-6","article-title":"The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens","volume":"86","author":"Brodie","year":"2003","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B231","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-374984-0.01078-0","article-title":"Nude Mouse","volume-title":"Brenner\u2019s Encyclopedia of Genetics","author":"Hoffman","year":"2013"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911944","article-title":"Intratumoral Treatment with 5-Androstene-3\u03b2, 17\u03b1-Diol Reduces Tumor Size and Lung Metastasis in a Triple-Negative Experimental Model of Breast Cancer","volume":"23","author":"Ruiz Manzano","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010424","article-title":"The Other Side of the Coin: May Androgens Have a Role in Breast Cancer Risk","volume":"23","author":"Chiodo","year":"2021","journal-title":"IJMS"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1087","article-title":"A New Approach to Reducing Postsurgical Cancer Recurrence: Perioperative Targeting of Catecholamines and Prostaglandins","volume":"18","author":"Neeman","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.970324","article-title":"Nanoformulation improves antitumor efficacy of MAOI immune checkpoint blockade therapy without causing aggression-related side effects","volume":"13","author":"Brown","year":"2022","journal-title":"Front Pharmacol"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001383","article-title":"Sertraline inhibits stress-induced tumor growth through regulating CD8+ T cell-mediated anti-tumor immunity","volume":"33","author":"Zhou","year":"2022","journal-title":"Anti-CA Drugs"},{"key":"B237","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1189\/jlb.5A1113-626RR","article-title":"Dopamine inhibits the function of Gr-1+CD115+ myeloid-derived suppressor cells through D1-like receptors and enhances anti-tumor immunity","volume":"97","author":"Wu","year":"2015","journal-title":"J Leukoc Biol"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.12.1147","article-title":"Dopamine Antagonists and the Development of Breast Cancer","volume":"59","author":"Wang","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2019.09.004","article-title":"Tramadol use is associated with enhanced postoperative outcomes in breast cancer patients: a retrospective clinical study with in vitro confirmation","volume":"123","author":"Kim","year":"2019","journal-title":"Br J Anaesth"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-598","article-title":"Fluoxetine modulates breast cancer metastasis to the brain in a murine model","volume":"14","author":"Shapovalov","year":"2014","journal-title":"BMC Cancer"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyac004","article-title":"Selective serotonin reuptake inhibitors associated with increased mortality risk in breast cancer patients in Northern Israel","volume":"51","author":"Fischer","year":"2022","journal-title":"Int J Epidemiol"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16646","article-title":"Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts","volume":"8","author":"Gwynne","year":"2017","journal-title":"Oncotarget"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1172\/JCI70982","article-title":"Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis","volume":"124","author":"Wu","year":"2014","journal-title":"J Clin Invest"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2022.10.016","article-title":"Deletion of monoamine oxidase A in a prostate cancer model enhances anti-tumor immunity through reduced immune suppression","volume":"634","author":"Lapierre","year":"2022","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1735300\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:23:22Z","timestamp":1771478602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1735300\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":244,"alternative-id":["10.3389\/fonc.2026.1735300"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1735300","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"article-number":"1735300"}}